Michael K. Borre, Ph.D.
Affiliations: | 2011 | Mechanical Engineering | University of Southern California, Los Angeles, CA, United States |
Area:
Mechanical EngineeringGoogle:
"Michael Borre"Parents
Sign in to add mentor| Henryk Flashner | grad student | 2011 | USC | |
| (Periodic solutions of flexible systems under discontinuous control.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fredsøe J, Glud E, Boesen L, et al. (2023) Danish Prostate Cancer Consortium Study 1 (DPCC-1) protocol: Multicentre prospective validation of the urine-based three-microRNA biomarker model uCaP. Bmj Open. 13: e077020 |
| Fredsøe J, Sandahl M, Vedsted P, et al. (2023) Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. European Urology Oncology |
| Borre M, Brodersen JB, Jacobsen H, et al. (2023) [Not Available]. Ugeskrift For Laeger. 185 |
| Fredsøe J, Rasmussen M, Tin AL, et al. (2022) Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Scientific Reports. 12: 15193 |
| Siltari A, Riikonen J, Koskimäki J, et al. (2022) Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. Bmj Open. 12: e050264 |
| Salachan PV, Rasmussen M, Fredsøe J, et al. (2022) Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Medicine. 14: 9 |
| Riedel M, Berthelsen MF, Cai H, et al. (2021) In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene |
| Haldrup J, Strand SH, Cieza-Borrella C, et al. (2020) FRMD6 has tumor suppressor functions in prostate cancer. Oncogene |
| Nguyen-Nielsen M, Møller H, Tjønneland A, et al. (2019) Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology. 64: 101623 |
| Nørgaard M, Haldrup C, Bjerre MT, et al. (2019) Epigenetic silencing of MEIS2 in prostate cancer recurrence. Clinical Epigenetics. 11: 147 |